Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · Real-Time Price · USD
3.090
+0.020 (0.65%)
At close: Dec 20, 2024, 4:00 PM
3.050
-0.040 (-1.29%)
After-hours: Dec 20, 2024, 4:47 PM EST
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for RVNC stock have an average target of 8.45, with a low estimate of 3.10 and a high estimate of 20. The average target predicts an increase of 173.46% from the current stock price of 3.09.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for RVNC stock from 9 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 1 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 4 | 7 | 7 | 6 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 12 | 11 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Hold Maintains $6.66 → $3.1 | Hold | Maintains | $6.66 → $3.1 | +0.32% | Dec 10, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $6.6 | Hold | Reiterates | $6.6 | +113.59% | Nov 8, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 28, 2024 |
| Barclays | Barclays | Buy → Hold Downgrades $10 → $7 | Buy → Hold | Downgrades | $10 → $7 | +126.54% | Sep 13, 2024 |
Financial Forecast
Revenue This Year
260.43M
from 234.04M
Increased by 11.28%
Revenue Next Year
331.29M
from 260.43M
Increased by 27.21%
EPS This Year
-1.63
from -3.83
EPS Next Year
-1.11
from -1.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 294.4M | 356.4M | 495.6M | |||
| Avg | 260.4M | 331.3M | 423.7M | |||
| Low | 236.3M | 279.4M | 305.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 25.8% | 36.9% | 49.6% | |||
| Avg | 11.3% | 27.2% | 27.9% | |||
| Low | 1.0% | 7.3% | -7.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.65 | -0.70 | 0.25 | |||
| Avg | -1.63 | -1.11 | -0.56 | |||
| Low | -1.61 | -1.45 | -1.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.